did fda ban semaglutide Drug compounders sue over declaration ending Wegovy shortage Compounded GLP-1 ban: What providers

Support responsiveness is just as important as shiny features

See: References Markey KA, Mollan SP, Jensen RH, et al

But, ultimately, the choice of which GLP-1 receptor agonist to use should be based on a patients specific medical needs, preferences, and discussions with a healthcare provider

What is semaglutide

Semaglutide was designed for continuous, long-term use rather than short-term weight loss cycles

Semaglutide mimics the GLP-1 hormone, an incretin, with 94% structural similarity to endogenous GLP-1, with modifications extending its half-life to 155184 h by reducing metabolic degradation, enhancing receptor affinity in organs such as the pancreas and hypothalamus, and increasing albumin binding